A Phase 1b/2 Multicenter, International, Randomized, Double Blind, Placebo-Controlled, Study of Gemcitabine Combined With PEGPH20 Compared to Gemcitabine Combined With Placebo in Patients With Stage IV Previously Untreated Pancreatic Cancer.

Trial Profile

A Phase 1b/2 Multicenter, International, Randomized, Double Blind, Placebo-Controlled, Study of Gemcitabine Combined With PEGPH20 Compared to Gemcitabine Combined With Placebo in Patients With Stage IV Previously Untreated Pancreatic Cancer.

Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 25 Jun 2016

At a glance

  • Drugs Hyaluronidase (Primary) ; Gemcitabine
  • Indications Pancreatic cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Halozyme Therapeutics
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 26 Jan 2016 Results published in the Clinical cancer research: an official journal of the American Association for Cancer Research.
    • 30 Sep 2013 Phase Ib results have been presented at the European Cancer Congress 2013 (ECCO-ESMO-ESTRO) according to a Halozyme Therapeutics media release. Results were also summarised in the media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top